Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJRFYB)

Drug Name

RG7201 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Sodium/glucose cotransporter 2 (SLC5A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[2]
Remogliflozin etabonate	DMW4YK1	Type-1/2 diabetes	5A10-5A11	Phase 2	[3]
Remogli ozin-etabonate	DMZFV3E	Type-2 diabetes	5A11	Phase 2	[4]
Ponalrestat	DM04ZUW	Gout	FA25	Discontinued in Phase 3	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium/glucose cotransporter 2 (SLC5A4)	TTN7Y4P	SC5A4_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
2	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4	Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25.
5	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).